PhaseBio Pharmaceuticals Inc (PHASQ)

[vwlibra]

PHAS upgraded by Zacks from a “hold” rating to a “buy” rating

https://dakotafinancialnews.com/2020/07/15/phasebio-pharmaceuticals-nasdaqphas-upgraded-to-buy-by-zacks-investment-research.html

PhaseBio Pharmaceuticals (NASDAQ:PHAS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. The brokerage presently has a $4.75 price target on the stock. Zacks Investment Research‘s target price indicates a potential upside of 0.42% from the stock’s current price.

A number of other research analysts have also weighed in on the company. Citigroup raised their price objective on PhaseBio Pharmaceuticals from $11.00 to $12.00 in a research report on Friday, May 29th. ValuEngine upgraded PhaseBio Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, March 17th. Needham & Company LLC started coverage on PhaseBio Pharmaceuticals in a research report on Thursday, May 28th. They issued a “buy” rating and a $18.00 price target for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $4.00 price target on shares of PhaseBio Pharmaceuticals in a research report on Tuesday, May 5th. Eight research analysts have rated the stock with a buy rating, PhaseBio Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $11.35.

Several large investors have recently made changes to their positions in PHAS. Wells Fargo & Company MN raised its stake in shares of PhaseBio Pharmaceuticals by 107.0% during the first quarter. Wells Fargo & Company MN now owns 16,832 shares of the company’s stock valued at $55,000 after acquiring an additional 8,699 shares in the last quarter. UBS Group AG raised its stake in shares of PhaseBio Pharmaceuticals by 39.8% during the fourth quarter. UBS Group AG now owns 18,059 shares of the company’s stock valued at $110,000 after acquiring an additional 5,139 shares in the last quarter. Barclays PLC raised its stake in shares of PhaseBio Pharmaceuticals by 41.1% during the fourth quarter. Barclays PLC now owns 21,969 shares of the company’s stock valued at $134,000 after acquiring an additional 6,403 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of PhaseBio Pharmaceuticals by 16.1% during the first quarter. Bank of New York Mellon Corp now owns 41,251 shares of the company’s stock valued at $136,000 after acquiring an additional 5,732 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its stake in shares of PhaseBio Pharmaceuticals by 14.8% during the first quarter. Nuveen Asset Management LLC now owns 42,501 shares of the company’s stock valued at $141,000 after acquiring an additional 5,488 shares in the last quarter. Institutional investors and hedge funds own 64.29% of the company’s stock.